Brokerages Set United Therapeutics Co. (NASDAQ:UTHR) PT at $388.25

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $388.25.

UTHR has been the subject of several research analyst reports. StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group lifted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th.

United Therapeutics Stock Up 0.6 %

Shares of United Therapeutics stock traded up $1.85 during trading on Friday, reaching $307.24. 494,807 shares of the stock were exchanged, compared to its average volume of 445,927. United Therapeutics has a 1 year low of $221.53 and a 1 year high of $417.82. The stock's fifty day moving average is $349.77 and its 200 day moving average is $358.48. The firm has a market cap of $13.80 billion, a price-to-earnings ratio of 13.49, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period last year, the business posted $4.36 earnings per share. Equities analysts forecast that United Therapeutics will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares of the company's stock, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nilda Mesa sold 255 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the sale, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 116,464 shares of company stock valued at $42,396,244 over the last 90 days. Corporate insiders own 11.90% of the company's stock.

Institutional Investors Weigh In On United Therapeutics

A number of large investors have recently added to or reduced their stakes in UTHR. Wealthfront Advisers LLC grew its position in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the period. Norges Bank bought a new stake in United Therapeutics in the 4th quarter worth approximately $151,764,000. FMR LLC grew its position in United Therapeutics by 36.5% in the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after purchasing an additional 393,777 shares during the period. World Investment Advisors LLC bought a new stake in United Therapeutics in the 3rd quarter worth approximately $139,206,000. Finally, Thrivent Financial for Lutherans grew its position in United Therapeutics by 1,325.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after purchasing an additional 189,967 shares during the period. Institutional investors own 94.08% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.